Anzeige
Mehr »
Samstag, 30.05.2026 - Börsentäglich über 12.000 News
Die nächste große Rohstoff-Sensation? Dieses Unternehmen besitzt das größte Wolfram-Portfolio der USA
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40YEP | ISIN: CA03835T4081 | Ticker-Symbol: LTI0
Stuttgart
29.05.26 | 21:57
1,410 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APTOSE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
APTOSE BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,3801,45029.05.
1,4101,49029.05.

Aktuelle News zur APTOSE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAptose Biosciences Inc (4): Aptose working to close Hanmi arrangement in June1
FrAptose Biosciences Inc. - 8-K, Current Report1
APTOSE BIOSCIENCES Aktie jetzt für 0€ handeln
FrAptose Biosciences, Inc.: Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical97SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement...
► Artikel lesen
14.05.Aptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks development1
13.05.Aptose Biosciences Inc. - 10-Q, Quarterly Report1
13.05.Aptose Biosciences Inc. - 8-K, Current Report1
13.05.Aptose Biosciences, Inc.: Aptose Reports First Quarter 2026 Results206SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...
► Artikel lesen
30.04.Aptose Biosciences Inc (4): Aptose awaits regulatory OK for closing of Hanmi deal1
30.04.Aptose Biosciences, Inc.: Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical142SAN DIEGO and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement...
► Artikel lesen
30.04.Aptose Biosciences Inc. - 8-K, Current Report-
18.04.Aptose Biosciences Inc (4): Aptose Biosciences delisting review extended4
31.03.Aptose Biosciences, Inc.: Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights781Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in "Go Private" transaction TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy...
► Artikel lesen
31.03.Aptose Biosciences Inc. - 10-K, Annual Report-
31.03.Aptose Biosciences Inc. - 8-K, Current Report-
23.03.Aptose Biosciences Inc (4): Aptose Bio gets Glass, Lewis support for takeover1
23.03.Aptose Biosciences, Inc.: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement1
19.03.Aptose Biosciences Inc. - 8-K, Current Report-
19.03.Aptose Biosciences, Inc.: Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical2
24.02.Aptose Biosciences Inc (4): Aptose delays vote, amends Hanmi deal1
24.02.Stocks in Play: Aptose Biosciences Inc.1
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1